SOPHiA GENETICS Raises $50M in Public Share Offering

Event summary

  • SOPHiA GENETICS priced a public offering of 10,526,000 ordinary shares at $4.75 per share, raising approximately $50 million.
  • The offering is expected to close on June 18, 2026, subject to customary closing conditions.
  • Underwriters have a 30-day option to purchase up to 1,578,900 additional ordinary shares.
  • TD Cowen is the lead book-running manager, with Guggenheim Securities, BTIG, and Craig-Hallum as additional managers.

The big picture

SOPHiA GENETICS' $50 million public offering reflects a strategic move to bolster its financial position in the competitive AI-driven precision medicine sector. The capital raise comes as the company seeks to expand its global network of healthcare institutions leveraging its SOPHiA DDM platform. This funding could accelerate its ability to deliver actionable insights for cancer and rare disorder treatments, positioning it for further market penetration.

What we're watching

Capital Deployment
How SOPHiA GENETICS will allocate the $50 million proceeds to drive growth in AI-driven precision medicine.
Market Positioning
Whether the capital raise strengthens SOPHiA GENETICS' competitive stance in the global precision medicine market.
Execution Risk
The pace at which the company can translate the funding into tangible advancements in its SOPHiA DDM platform.